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Prevalence and risk factors for mast cell tumours
in dogs in England
Stephanie JW Shoop1*, Stephanie Marlow2, David B Church3, Kate English4, Paul D McGreevy5, Anneliese J Stell3,
Peter C Thomson5, Dan G O’Neill2 and David C Brodbelt2

Abstract
Background: Mast cell tumour (MCT) appears to be a frequent tumour type in dogs, though there is little
published in relation to its frequency in dogs in the UK. The current study aimed to investigate prevalence and risk
factors for MCTs in dogs attending English primary-care veterinary practices.
Methods: Electronic patient records from practices participating in the VetCompass animal surveillance project
between July 2007 and June 2013 were searched for MCT diagnosis. Various search terms and standard diagnostic
terms (VeNom codes) identified records containing MCT diagnoses, which were evaluated against clinical criteria for
inclusion to the study. MCT prevalence for the entire dataset and specific breed types were calculated. Descriptive
statistics characterised MCT cases and multivariable logistic regression methods evaluated risk factors for association
with MCT (P < 0.05).
Results: Within a population of 168,636 dogs, 453 had MCT, yielding a prevalence of 0.27% (95% confidence
interval (CI) 0.24% - 0.29%). The highest breed type specific prevalences were for the Boxer at 1.95% (95% CI
1.40% - 2.51%), Golden Retriever at 1.39% (0.98% - 1.81%) and Weimaraner at 0.85% (95% CI 0.17% to 1.53%).
Age, insurance status, neuter status, weight and breed type were associated with MCT diagnosis. Of dogs of
specific breed type, the Boxer, Pug and Staffordshire Bull Terrier showed greater odds of MCT diagnosis compared
with crossbred dogs. Conversely, the German Shepherd Dog, Border Collie, West Highland White Terrier, Springer
Spaniel and Cocker Spaniel had reduced odds of MCT diagnosis compared with crossbred dogs. No association
was found between MCT diagnosis and sex.
Clinical significance: This study highlights a clinically significant prevalence of MCT and identifies specific breed
types with predisposition to MCT, potentially aiding veterinarian awareness and facilitating diagnosis.
Keywords: Mastocytoma, Mast cell, Canine, Prevalence, Primary-care practice, Epidemiology, Oncology

Lay summary
Mast cell tumour (MCT) is the most common skin
tumour type in dogs, but little is known about its frequency in the general dog population nor its frequency
in particular dog breeds in the UK. This study has investigated the frequency of the disease, and possible risk
factors associated with the development of MCT.
This has been conducted by analysing the large number of electronic patient health records contained within
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the VetCompass animal surveillance project collected
between July 2007 and June 2013.
Data were available on a population of 168,636 dogs
and within this 453 (0.27%) had MCT. The breeds with
the highest breed specific prevalences were Boxer, Golden
Retriever and Weimaraner. Conversely, some breeds
appeared to be protected.
Age, insurance status, neuter status, weight and breed
type were associated with MCT diagnosis. No association
was found between MCT diagnosis and gender.
Such information helps to increase awareness of this
condition, particularly in certain breeds, to owners and
veterinarians.

© 2015 Shoop et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
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Background
Mast cell tumours (MCTs) are a frequent tumour type
in dogs [1], accounting for 7-21% of cutaneous tumours
diagnosed [1-4]. Dobson and others (2002) reported the
incidence of MCT in English dogs as 129 in 100,000
dogs per year [5]; however, this study was limited to insured animals and thus may generalise poorly to the
wider population of dogs in England. MCTs occur primarily in the dermis and subcutaneous tissues and can
be confirmed in 92-96% of cases through fine needle aspirate (FNA) cytology [6]. Histopathology allows description of the degree of MCT malignancy and clinical
grading [6] using two grading systems. Using the Patnaik
system, MCTs are categorised into three grades (I, II &
III), the third being more clinically important because
tumours of this grade are often more aggressive and
may metastasise [7]. The more recently proposed Kiupel
two tier system categorises MCTs into high or low-grade
in order to increase concordance among veterinary pathologists [8].
There are likely to be many factors contributing to the
development of MCT which may be genetically influenced [6]. Up to 40% of dogs with subcutaneous and cutaneous MCTs have been found to have mutations in a
proto-oncogene, c-kit [6]. Other potential factors include
neuter status, sex, age, weight, insurance status and specific breed types. Females [9], and particularly neutered
females [10] have been associated with increased risk of
MCT in some studies, although other studies failed to
identify an association between sex and MCT [11,12].
While the mean age at presentation of cutaneous MCTs
has been reported at between 7.5 and 9 years old [9],
one study found poorly differentiated (grade III) tumours more common in younger dogs, although the
study population consisted of only one breed, the
Shar-Pei [13]. Likewise, while one study found no difference in pre-disposition to MCTs between dogs of
specific breed types and mixed breed (crossbred) dogs
overall [14], certain breed types have previously been
associated with this condition. Most commonly, Boxers
and Golden Retrievers [10,15,16] and other larger breed
types have been associated with pre-disposition to MCT
whereas smaller breed types are reported to be at lower
risk of the condition [10]. Less commonly, breed types
including Pugs [10,17], Weimaraners [15,16] and the
mastiff and terrier phylogenetic clusters [10] have also
been associated with having MCTs.
This study aimed to estimate the prevalence and explore risk-factors for the development of MCTs in dogs,
using a large sample of animals attending primary-care
veterinary practices in England. By identifying factors associated with a higher risk of developing MCTs, it was
hoped to improve the index of suspicion for this disease
and hence early recognition of this important condition.
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Results
The VetCompass system documented 168,636 dogs from
a total of 94 veterinary practices within England between
28th June 2007 and 30th June 2013. Of these, 453 dogs
met the clinical criteria for inclusion to the study and
were classified as dogs presenting with MCT at a participating veterinary practice during the study period.
Thus, the MCT prevalence was estimated at 0.27%
(95% CI 0.24% to 0.29%) over the study period. Individual breed type MCT prevalences that exceeded this
overall estimate included that of the Boxer at 1.95%
(95% CI 1.40% to 2.41%), the Golden Retriever at
1.39% (95% CI 0.98% to 1.81%), the Weimaraner at
0.85% (95% CI 0.17% to 1.53%), the Labrador Retriever
at 0.72% (95% CI 0.58% to 0.85%), the Staffordshire Bull
Terrier at 0.51% (95% CI 0.39% to 0.62%) and the Pug
at 0.50% (95% CI 0.13% to 0.88%). Individual breedtype MCT prevalences that fell below the overall estimate included the Springer Spaniel at 0.20% (95% CI
0.06% to 0.35%), the Jack Russell Terrier at 0.16% (95%
CI 0.09% to 0.23%), the West Highland White Terrier
at 0.07% (95% CI 0.00% to 0.15%), the Border Collie at
0.07% (95% CI 0.00% to 0.14%), the Cocker Spaniel at
0.06% (95% CI 0.00% to 0.12%), the Yorkshire Terrier
at 0.04% (95% CI 0.00% to 0.09%) and the German
Shepherd Dog at 0.02% (95% CI 0.00% to 0.05)
(Table 1A). Overall MCT prevalence for dogs of specific
breed types was 0.29% (95% CI 0.26 – 0.32%) and overall
crossbred prevalence was 0.18% (95% CI 0.14 – 0.22)
(Table 1B).
Of the cases, 48% were male (n =218), 64% insured
(n =291) and 71% neutered (n =323). The median age
at diagnosis was 8.2 years (interquartile range (IQR)
6.0 to 10.2 yr) and median weight 27.7 kg (IQR 20.0 to
34.2 kg).The most common breed types affected were
the Labrador Retriever (23%, n =106), Staffordshire
Bull Terrier (16%, n =72), Boxer (10%, n =47), Golden
Retriever (9%, n =43), Jack Russell Terrier (4%, n =18),
Springer Spaniel (2%, n =8), Pug (2%, n =7) and Weimaraner
(1%, n =6). Fourteen percent were crossbred (n =65).
Of the controls, 52% were male (n =1,067), 26% insured (n =527) and 40% neutered (n =820). The median age was 3.1 years (IQR 0.5 to 7.2 yrs) and median
weight 11.6 kg (IQR 6.0 to 24.7 kg). The most common
control breed types were the Labrador Retriever (11%,
n =215), Staffordshire Bull Terrier (8%, n =159), Jack
Russell Terrier (8%, n =155), Cocker Spaniel (4%, n =86),
West Highland White Terrier (3%, n =66), German
Shepherd Dog (3%, n =63), Border Collie (3%, n =60),
Yorkshire Terrier (3%, n =57), Springer Spaniel (2%, n
=50) and Golden Retriever (2%, n =39). Nineteen percent were crossbred (n =391). The 453 cases and 2,036
controls (1:4 case to control ratio) were taken forward
for evaluation of risk factors for a diagnosis of MCT.
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Table 1 Breed-type specific prevalence of mast cell tumour (MCT) diagnosis with 95% confidence intervals (CI)
A) Specific breed types
Breed-type

Cases (n)

Total (n)

MCT prevalence (%)

95% CI (%)

Boxer

47

2406

1.95

1.40 - 2.51

Golden Retriever

43

3086

1.39

0.98 - 1.81

Weimaraner

6

705

0.85

0.17 - 1.53

Labrador Retriever

106

14781

0.72

0.58 - 0.85

Staffordshire Bull Terrier

72

14219

0.51

0.39 - 0.62

Pug

7

1391

0.50

0.13 - 0.88

Springer Spaniel

8

3906

0.20

0.06 - 0.35

Jack Russell Terrier

18

11333

0.16

0.09 - 0.23

West Highland White Terrier

3

4254

0.07

0.00 - 0.15

Border Collie

3

4501

0.07

0.00 - 0.14

Cocker Spaniel

4

6353

0.06

0.00 - 0.12

Yorkshire Terrier

2

5512

0.04

0.00 - 0.09

German Shepherd Dog

1

5993

0.02

0.00 - 0.05

Specific breed type

388

132139

0.29

0.26 – 0.32

Crossbred

65

36361

0.18

0.14 - 0.22

Unknown breed

0

136

-

-

Total

453

168636

0.27

0.24 – 0.29

B) Summary results

Dogs were recruited from a VetCompass population of 168,636 dogs. Breed types are listed from highest to lowest prevalence.

Risk factor analysis

Univariable analysis identified insured and entire dogs as
having significantly increased odds of MCT. Weight and
age were also associated with MCT, with the categories
at highest odds being 30.01 to 40.00 kg, compared to
≤10.00 kg and 8 to 10 years of age, compared to ≤2.00 years,
respectively (Table 2). In addition, the proportion of certain
breed types in case and control groups differed (Figure 1),
suggesting at least a univariate association between specific
breed type and MCT diagnosis. In particular, the Labrador
Retriever, Staffordshire Bull Terrier, Golden Retriever,
Boxer, Pug and Weimaraner appeared to be more frequently represented among cases than controls. There was
also a significantly larger proportion of specific breed types
compared to crossbreds in case compared to control samples. There was no significant difference in sex between the
two groups (Table 2).
All variables tested showed at least a general trend
(P ≤0.25) of association with the outcome (Table 2),
and were taken forward for evaluation in the multivariable
analysis [18] (Table 3). The multivariable model identified
age, insurance status, weight, neuter status and specific
breeds as statistically significantly associated with MCT
diagnosis. Sex was not significantly associated with MCT
diagnosis (P =0.18).
Dogs over 10 years old had 41.3 times the odds of
MCT diagnosis compared with dogs under 2 years old

(95% CI 16.7 to 102.5). Dogs of weight 20 to 30 kg had
2.6 times the odds of MCT diagnosis compared with
those under 10 kg (95% CI 1.4 to 4.8). Insured dogs were
at 3.1 times the odds (95% CI 2.2 to 4.5) and neutered
dogs were at 0.1 times the odds of having MCT (95% CI
0.1 to 0.2) compared to uninsured and entire dogs respectively (Figure 2). Of specific breed types, the Boxer
was at 10.7 times (95% CI 3.7 to 30.4), Pug at 10.0 times
(95% CI 1.5 to 64.5) and Staffordshire Bull Terrier at 4.2
times the odds (95% CI 2.2 to 8.2) of having MCT compared with crossbred dogs. Conversely, the German
Shepherd Dog was at 0.0 times (95% CI 0.0 to 0.4),
Border Collie at 0.1 times (95% CI 0.0 to 0.5), West
Highland White Terrier at 0.2 times (95% CI 0.0 to 0.8),
Springer Spaniel at 0.3 times (95% CI 0.1 to 0.9), and
Cocker Spaniel at 0.3 times the odds (95% CI 0.1 to 0.9)
of having MCT compared with crossbred dogs. No association was found between sex and MCT diagnosis.
Dogs of all other specific breed types other than those
individually analysed were at 0.4 times the odds of having
MCT than crossbreds (95% CI 0.3-0.0.7). When comparing all specific breed types versus all crossbreds without
testing for individual breed effects in the multivariable
model, no significant difference in MCT predisposition
was observed (P =0.762). A significant interaction was observed between weight and the specific breed type variable, but a likelihood ratio test suggested no significant
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Table 2 Risk factors for mast cell tumour (MCT) from univariable analysis
Variable

Category

Case

Control

OR

Age

≤2.0 years

8

840

1(base)

95% CI

P-value

2.0-4.0 years

22

301

7.7

3.4-17.4

<0.001

4.0-6.0 years

60

245

25.7

12.1-54.5

0.038

6.0-8.0 years

82

199

43.3

20.-90.9

<0.001

8.0-10.0 years

95

171

58.3

27.8-122.3

<0.001

<0.001

>10.0 years

108

267

42.5

20.4-88.2

<0.001

Age (continuous)

Median (IQR) (years)

8.2 (6.0 - 10.2)

3.1 (0.5 – 7.2

1.2

1.2-1.3

<0.001

Breed Type

Crossbred

65

391

1(base)

Boxer

47

22

12.9

7.3-22.7

<0.001

Golden Retriever

43

39

6.6

4.0-11.0

<0.001

Weimaraner

6

9

4.0

1.4-11.6

0.028

Labrador Retriever

106

215

3.0

2.1-4.2

<0.001

Pug

7

15

2.8

1.1-7.2

0.096

Staffordshire Bull Terrier

72

159

2.7

1.9-4.0

<0.001

Springer Spaniel

8

50

1.0

0.4-2.1

0.379

Purebred status

Insurance status

Jack Russell Terrier

18

155

0.7

0.4-1.2

0.006

Border Collie

3

60

0.3

0.1-1.0

0.005

Cocker Spaniel

4

86

0.3

0.1-0.8

0.001

West Highland White Terrier

3

66

0.3

0.1-0.9

0.002

Yorkshire Terrier

2

57

0.2

0.1-0.9

0.003

German Shepherd Dog

1

63

0.1

0.0-0.7

<0.001

0.4-0.9

0.456

1.1-1.9

0.016

4.1-6.4

<0.001

0.2-0.4

<0.001

Other specific breed type

68

649

0.6

Crossbred

65

391

1(base)

Of breed type

388

1654

1.4

Not insured

162

1502

1(base)

Insured

291

527

5.1

Neuter status

Entire

130

102

1(base)

Neutered

323

820

0.3

Sex

Female

233

956

1(base)

Weight

Weight (continuous) (kg)

0.016

Male

218

1067

1.2

≤10.0 kg

49

771

1(base)

1.0-1.5

0.090

10.0-20.0 kg

60

379

2.5

1.7-3.7

<0.001

20.0-30.0 kg

145

296

7.7

5.4-10.9

<0.001

<0.001

30.0-40.0 kg

135

197

10.8

7.5-15.5

<0.001

>40.0 kg

46

79

9.2

5.8-14.6

<0.001

Median (IQR)

27.7 (20.0 - 34.2)

11.6 (6.0 – 24.7)

1.1

1.1-1.1

<0.001

Odds ratios (OR) with 95% confidence intervals (CI) are reported. Cases (n = 453) and controls (n = 2036) were selected from a VetCompass population of
168,636 dogs.

improvement to model fit (P >0.5), so this interaction was
not retained. No other interactions were retained in the
final model. Good final model fit was suggested by a
Hosmer-Lemeshow test (P =0.831). Clustering at the clinic
level was evaluated with clinic ID entered as a random
effect but was not statistically significant and therefore
was not retained (P =0.49).

Discussion
This study identified a prevalence of MCT of 0.27%
(95% CI 0.24% to 0.29%) over the study period and
demonstrated associations between age, insurance status
and specific breed types with MCT diagnosis. Highest
MCT breed type prevalences were identified for the
Boxer at 1.95% (95% CI 1.40% - 2.51%), Golden Retriever
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Figure 1 Percentage of mast cell tumour (MCT) positive and non-MCT dogs attributed to specific breeds. 95% confidence intervals are
displayed relating to these values. Cases (n = 453) and controls (n = 2036) were selected from a VetCompass population of 168,636 dogs.

at 1.39% (0.98% - 1.81%) and Weimaraner at 0.85% (95%
CI 0.17% to 1.53%). A previous study estimated an incidence of MCT among insured UK dogs of 129 in
100,000 dogs per year (95% CI 107 to 145) [5]. However,
as this study’s population was limited to insured animals,
the results may not generalise well to the overall dog
population. Insured dogs are more likely to be younger
[5], as policies are often cancelled in older dogs [19] and
more likely to be of specific breed-types [20]. Insured
dogs are also more likely to undergo further diagnostic
testing and treatments [21] compared with uninsured
dogs, which potentially led to an overestimation of MCT
incidence by Dobson and others [5]. Conversely, insurance data may underestimate true incidence of MCT as
only cases that are not excluded and whereby the deductible excess does not exceed the cost of diagnosis
and treatment are included [21]. Therefore, the estimate
reported in the current study is more generalisable to
practice-attending dogs and to the general canine population in England. A Dutch study estimated incidence at
265 in 100,000 dog-years and focused purely on Labrador Retrievers [22]. It is likely that the latter’s incidence
estimation was much larger due to the potential predisposition of Labrador Retrievers to purely cutaneous
MCTs [10,23,24]. Whilst Labrador Retrievers were not
found to have a significant association with MCT diagnosis in the current study, it may be that this breed type
is associated with only cutaneous MCTs or the current
finding may highlight differences between study populations. Incidence was not calculated in the current study
as it was not always clear if the cancer cases were newly

diagnosed, hence it was considered more reliable to report the frequency of all existing cases in relation to all
practice attending dogs during the study period and thus
period prevalence. In a large study in the US, Villamil
and others (2011) reported 0.25% of 1,139,616 dogs analysed were diagnosed with cutaneous MCT [23], similar
to the current study’s estimation.
The current study identified that older dogs were at
increased odds of MCT, with those over 10 years being
around 41 times greater odds than those under 2 year of
age. Previous studies have also found older dogs to be
more susceptible to MCTs [23,25], consistent with the
findings of the current study, with the average age for
MCT diagnosis in dogs between 7.5-9 years of age [9].
In the current study, the median age of cases at presentation was 8.2 years (IQR 6.0-10.2 yr), compared to that
of controls which was 3.1 years (IQR 0.5-7.2 yr). In summary, the current findings suggest that MCTs generally
present in older dogs. A study focusing on Shar-Peis
identified younger animals (median age 5 years) to be
commonly afflicted with high grade MCTs, with 28% of
cases under 2 years of age [13]. However, the small
sample size (n =18) and single breed make it difficult to
generalise the results from this earlier study.
Insured dogs had a higher odds of MCT compared
with the control group in the current analysis. Biological
differences between insured and uninsured dogs may
have partially accounted for this association, as a higher
percentage of dogs of some specific breed types have
been reported to be insured compared with crossbreds
[21]. Conversely, insurance cover is frequently cancelled
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Table 3 Risk factors for mast cell tumour (MCT) from final multivariable binary logistic regression model
Variable

Category

Case

Control

OR

Age

≤2.0 years

8

840

1(base)

2.0-4.0 years

22

301

5.7

2.1-15.2

0.001

4.0-6.0 years

60

245

15.9

6.2-40.4

<0.001

6.0-8.0 years

82

199

18.3

7.3-45.9

<0.001

8.0-10.0 years

95

171

38.3

15.1-97.4

<0.001

>10.0 years

108

267

41.3

16.7-102.5

<0.001

Crossbred

65

391

1(base)

Boxer

47

22

10.7

3.7-30.4

<0.001

Pug

7

15

10.0

1.5-64.5

0.016

Breed type

Insurance Status

Neuter Status

Weight

95% CI

P value
<0.001

<0.001

Staffordshire Bull terrier

72

159

4.2

2.2-8.2

<0.001

Golden Retriever

43

39

2.0

0.9-4.5

0.080

Weimaraner

6

9

1.4

0.2-9.8

0.718

Labrador Retriever

106

215

1.3

0.8-2.3

0.319

Jack Russell Terrier

18

155

0.9

0.4-2.1

0.790

Cocker Spaniel

4

86

0.3

0.1-0.9

0.037

Springer Spaniel

8

50

0.3

0.1-0.9

0.029

West Highland White Terrier

3

66

0.2

0.0-0.8

0.030

Border Collie

3

60

0.1

0.0-0.5

0.004

Yorkshire Terrier

2

57

0.1

0.0-1.0

0.053

German Shepherd Dog

1

63

0.0

0.0-0.4

0.007

Other specific breed type

68

649

0.4

0.3-0.7

0.001

2.2-4.5

<0.001

0.1-0.2

<0.001

Not Insured

162

1502

1(base)

Insured

291

527

3.1

Entire

130

102

1(base)

Neutered

323

820

0.1

≤10.0 kg

49

771

1 (base)

10.0-20.0 kg

60

379

1.1

0.6-2.1

0.744

20.0-30.0 kg

145

296

2.6

1.4-4.8

0.002

30.0-40.0 kg

135

197

2.5

1.3-4.9

0.007

>40.0 kg

46

79

2.6

1.2-5.6

0.017

0.004

Odds ratios (OR) with 95% confidence intervals (CI) are reported. Cases (n = 453) and controls (n = 2036) were selected from a VetCompass population of
168,636 dogs.

in older dogs and so the insured group may have underrepresented older dogs that had increased odds of MCT.
However, diagnostic testing and treatments likely differed between insured and non-insured dogs. Insured
dogs may have been more likely to undergo further tests
that confirm MCT [21], and therefore to have met clinical criteria for inclusion to the study.
Similar to Peters and others [11] and Miller [13], the
current study found no association between sex and
MCT. Consistent with the findings of White and colleagues [10] and Zink and others [26], the current study
also reported an association between neuter status and
MCT development. However, whilst Zink and others
[26] reported increased odds of MCT for neutered

Vizslas and White and others [10] reported an increased
risk of MCT for neutered females, the current study
found decreased odds of MCT for neutered dogs in general. However, limitations of the present study may also
contribute to these conflicting findings. In the practice
management systems, each dog was assigned one neuter
status which was promptly updated without notification
of date when this status changed. At the time of the data
query, neuter status may have been different from that
when initial MCT diagnosis was made, therefore this
study may have underestimated the number of dogs with
MCT that were entire at diagnosis. Further investigation
into a potential association between neuter status in
both sexes and MCT diagnosis is merited.
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Figure 2 Risk factors for mast cell tumour (MCT) from final multivariable binary logistic regression model. Odds ratios for MCT with
corresponding 95% confidence intervals are reported. Dogs weighing less than 10 kg and aged less than 2 yrs have odds ratios of 1 as were used
as baseline categories for weight and age variables respectively.

Previous studies describing risk-factors for MCT were
mainly limited to specific breed types, focused purely on
cutaneous MCTs and had smaller sample sizes than the
current study. Larger-sized breeds were previously reported at higher risk of developing MCT than smaller
and medium breeds [10]. Similarly, the current study
found that dogs over 20 kg had over twice the odds of
having MCT compared to those under 10 kg. The
current study also supports the findings of a large US
study of no difference in MCT diagnosis between dogs
of specific breed types and crossbred dogs in general
[14]. This is likely a product of increased risk for a few
specific breed types and decreased risk for the majority
of dogs of other breed types, supported by the significantly decreased MCT odds for the ‘other specific breed
type’ category in the present analysis.
The current study supports the general consensus that
Boxers have increased risk of MCTs [10,11,15,16,23,25,27].
Consistent with previous work [11,16,23], the study also
identified Staffordshire Bull Terriers as being at higher
odds and it is hypothesised that their predisposition, including that of Boxers and other bull-type breeds, may be
linked to common ancestry [11] since these breed types
are closely phylogenetically clustered [27]. As also reported by Murphy and others [16], Villamil and others
[23], White and others [10] and McNiel and others [17],
the current study identified Pugs as having high odds of
developing MCTs. Golden Retrievers [10,15,16,23,27],
Labrador Retrievers [10,23,24] and Weimaraners [15,16,27]
have previously been found to be at high risk of cutaneous
MCTs. Though the current study reports trends supporting

these findings, it did not detect a statistically significant
association for the Golden Retriever, Labrador Retriever
or the Weimaraner compared to crossbred dogs. However,
given the small sample size for Weimaraners (case n =6,
control n =9), the current study may have had limited
power to explore infrequently presented breed types and
smaller magnitudes of association. This study corroborates
previous work that found German Shepherd Dogs [23,27],
Cocker Spaniels, West Highland White Terriers and
Border Collies to be at decreased odds of MCT [27] compared to crossbred dogs. However, in contrast to previous
work this study did not detect a reduction in odds of
MCT in Yorkshire Terriers [10,23].
Some limitations to the current study are worth noting.
When assessing common breed types in control samples,
a number had small sample sizes in the case group. Border
Collies, German Shepherd Dogs, Weimaraners, West
Highland White Terriers and Yorkshire Terriers were analysed separately because previous studies suggested protective effects for these breed types [10,23,27]. This may
be an effect of partial confounding by age. The case group
will have had older dogs than the control group as older
dogs were at greater odds of MCT and therefore fewer
dogs of large breed type, which have been reported to have
shorter longevity [28]. However, age of dogs was retained
in the final multivariable model and should have, at least
in part, adjusted for this association between breed and
age structure. Matching cases to controls based on a similar age-structure may have improved interpretation of
breed type associations with MCT, but would have prevented investigation into any association between age and
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this condition. Based on the stated case definition, the
prevalence of MCT was likely to be under-estimated. Subcutaneous tumours may be less likely to be diagnosed
compared with cutaneous MCTs because of their less
prominent nature. In addition, some dogs with MCT will
have been excluded from the case sample where a diagnosis of MCT was made but no definitive laboratory results
from FNA or histopathology were recorded. This included
dogs where a history of MCT only was cited and where a
MCT diagnosis was recorded but euthanasia followed
without a definitive test. Likewise, in a small number of
dogs, an impression smear alone was used to diagnose
MCT. Whilst in theory an MCT diagnosis could be obtained from an ulcerated mass through an impression
smear, if there is superficial inflammation associated with
the lesion, the smear may be difficult to interpret [29].
Conversely, it was possible that controls may have had
MCTs, but by excluding dogs with any mention of mast
cell in their case notes, this study aimed to minimise the
number of misclassified controls. Insurance status of study
dogs may not have been completely accurate. Where there
were no insurance data at the date of diagnosis for case
dogs, the nearest possible previous insurance status was
used. Thus, insurance status may have changed without
documentation by the date of diagnosis. For controls, the
nearest possible insurance status was used as the date of
first presentation to a veterinarian.

Conclusion
This study estimated a clinically relevant prevalence of
MCT in dogs attending primary-care practices in England
at approximately 0.27% (95% CI 0.24% to 0.29%) and
identified associations with older, insured, heavier dogs,
and specific breed types with diagnosis. Boxers, Pugs
and Staffordshire Bull Terriers were at increased
odds of MCT compared to crossbred dogs. Conversely, German Shepherd Dogs, West Highland White
Terriers, Border Collies and Cocker Spaniels were at lower
odds of MCT. Further investigation is warranted to explore MCT occurrence in less common breed types as
well as associations with subcutaneous MCT and malignancy severity.
Method
The study population was selected from the VetCompass
animal surveillance database [30], which documents clinical records from English primary-care veterinary practices. Data relating to clinical consultations between 28th
June 2007 and 30th June 2013 were collected from a group
of practices using VetCompass predominantly in central
and south eastern England. Electronic patient record
(EPR) data included a summary diagnosis term selected
from a list of standardised veterinary nomenclature (VeNom)
codes, developed by the VeNom Coding Group [31], which
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were selected by clinicians at the time of the ‘episodes of
care’. Additional clinical fields collected included unique
animal and clinic identification numbers, date of birth,
breed type, sex, neuter status, weight, insurance status,
episode of care date, clinical notes and details of specific
diagnosis, confirmatory testing methods and treatments
including any surgical procedures. Institutional ethics
approval was gained (RVC URN 2001 1101).
The case definition for MCT included evidence of a
final diagnosis of MCT recorded either by a veterinarian
within the clinical notes or on an insurance claim submission. Additionally, evidence of results from a combination
of fine needle aspirate (FNA) cytology and/or biopsy
histopathology was required to confirm this diagnosis.
Dogs that had confirmatory testing using only impression
smears were not included due to difficulty in the interpretation of such smears [29]. Cases were identified from the
clinical notes based on this case definition, via the standard diagnosis (VeNom codes) and the clinical free text
notes. Search terms applied for the free text clinical notes
included ‘mast cell’, ‘mast_’, ‘mct’ and ‘masto’.
Control animals were selected using a random number
generator [32] from dogs not diagnosed with MCT. Since
minimal increase in statistical power can be gained beyond
four controls per case [33], a subset of control animals
were selected at a 1:4 case to control ratio [34]. Controls
were not matched to cases on any clinical or phenotypical
criteria in order to avoid excluding any potential risk factors for MCT from the analysis. Therefore, characteristics
of controls derived randomly from the VetCompass database were likely to reflect the general practice attending
canine population. These random numbers were then associated with unique patient identification numbers using
the VLOOKUP function in Microsoft Excel 2010 [35].
Controls were excluded if they had evidence of suspicion
or confirmation of MCT or no evidence of presentation to
a veterinary surgeon within the existing case notes. Risk
factors tested for association with MCT were age, sex, insurance status, neuter status, weight and breed type.
Prevalence of MCT diagnosis was estimated from the
number of cases divided by the population of dogs documented in the VetCompass system throughout the study
period. Prevalence of MCT diagnosis for individual breed
types over the study period was calculated from the number
of MCT cases of a specific breed type divided by the population of dogs of the same breed type in the VetCompass
system presenting to participating practices during the
study period. A nested case–control study design identified risk factors associated with MCT diagnosis.
Data analysis

Before importation into IBM SPSS version 20 statistical
software for analysis [36], data were imported into
Microsoft Excel 2010 to be cleaned and to produce one
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record per dog. Dates of confirmation of MCT diagnosis
for cases, and for controls dates of first recorded presentation to the veterinarian were used in combination with
dates of birth to calculate ages. Insurance status on dates
that directly preceded the first date of confirmed diagnosis was used for cases and insurance status nearest the
first presentation was used for controls. Weights used
were those documented nearest the date of diagnosis
confirmation for cases and first presentation for controls. Breed type was recorded at the originating practices based on consensus between the practice and
owners. The breed types recorded were mapped to the
specific breed terms within the VeNom coding system
during the analysis and were reduced into 15 categories.
These categories derived from the top 10 most common
case breed types and top 10 most common control breed
types along with a ‘other specific breed type’ and a
‘crossbred’ category, defined as dogs of mixed breed.
‘Crossbred’ dogs were retained as a separate group and
used as the comparator group for the breed-type analyses because of a prevailing opinion that health characteristic may vary between dogs of specific breed types
and crossbred dogs due to a higher degree of homozygosity within the breed types [14,37,38]. Crossbreds included all dogs that were not classified as breed types
regardless of the suspected number of progenitor breeds
in the parentage and were used as the comparator group
based on their suspected higher general degree of heterozygosity. Further separation of crossbreds into those
dogs with just two specific parental breed types and
those with more mixed ancestry was not possible at
this stage.
Univariable analysis assessed associations between risk
factors and a diagnosis of MCT using Chi-squared and
Mann–Whitney U-test for categorical and quantitative
data respectively because data were non-normally distributed. Broadly significant variables from the univariable
analysis (P ≤0.25) were taken forward for consideration in
the multivariable logistic regression model [18]. Collinearity
of variables taken forward was explored via standard statistical methods [39]. A manual forward selection step-wise
construction method was taken for model building with
statistical significance set at the 5% level. The forward
step-wise regression used the likelihood ratio test. Clustering at the clinic level was evaluated with the addition of
clinic ID as a random effect. Final variables were evaluated
for pairwise interactions and the final model was evaluated
with the Hosmer-Lemeshow goodness-of-fit test [40].
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